fda news tirzepatide The @U.S. Food and Drug Administration (@fda ) has accepted @Sandoz 's applications for review of two generic versions of tirzepatide, the active ingredient in Eli Lilly and Company 's blockbuster drugs 2026 FDA Rules and News

Melanie Avalon Thank you

Compounding allows for alternative delivery methods including oral troches, sublingual drops, or nasal spray formulations, expanding the patient population your practice can serve

HypoSpray is a proprietary transdermal delivery technology developed, owned, and controlled by TDSC / HypoSpray Pharma, and ARSYNL Rx may provide provider-guided access when clinically appropriate

Understanding optimal use parameters prevents most problems before they start

Our program is designed to help you incorporate this medication into a comprehensive weight loss plan that includes a custom diet plan and ongoing support from our team of medical weight loss experts